Crown Bioscience Inc.
CrownBio Expands Novel Humanized Models for Targeted Immunotherapy Development to San Diego, CA Research Center
Humanized Model Expansion Program begins with PD-1, CTLA-4, and CD137 Models
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, extends its existing portfolio of humanized drug target models (HuGEMM(TM)) to its San Diego facility.
This service offering expansion to the San Diego site will begin with humanized PD-1, PD-L1, CTLA-4, OX40, CD137, PD-1/PD-L1, and PD-1/CTLA-4 targets. Additional HuGEMM(TM) models will follow later this year to help advance development of immuno-oncology (I/O) drugs.
The expansion of this novel translational platform to CrownBio's San Diego laboratory makes it more accessible to both the North American and worldwide research community.
CrownBio provides the biopharmaceutical research community with innovative preclinical platforms to evaluate human-specific immunotherapies in vivo, while shortening experimental timelines and mitigating costs. The HuGEMM portfolio helps achieve this by featuring fully functional murine immunity with a humanized drug target that can be used in conjunction with syngeneic/homograft mouse tumors.
"Our HuGEMM portfolio is uniquely positioned to expedite study timelines, save researcher's money and deliver valuable insights about targeted immunotherapies," said Henry Li, PhD, Senior Vice President of Global Scientific Research and Innovation. "We are very excited about continuing to grow this platform and to make it more available to scientists globally via the expansion of our San Diego laboratory."
Learn more about CrownBio's HuGEMM models by visiting:
About Crown Bioscience
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Scrum Alliance18.9.2018 16:04 | pressemeddelelse
FOUR IN FIVE EXECUTIVES AGREE AGILITY IS MOST IMPORTANT CHARACTERISTIC OF A SUCCESSFUL ORGANIZATION
Harbert Management Corporation18.9.2018 14:38 | pressemeddelelse
Harbert European Growth Capital Announces Final Close
Teledyne DALSA18.9.2018 14:32 | pressemeddelelse
Teledyne DALSA expands its area camera series with the industry’s first 5 Gigabit, GigE Vision models
Talend18.9.2018 14:01 | pressemeddelelse
Talend Supports La Mutuelle Générale to Power its AWS Cloud Data Lake
Crown Bioscience18.9.2018 14:01 | pressemeddelelse
CrownBio Licenses Translational Breast Cancer Models of Resistance and Metastasis
Nuvaira, Inc.18.9.2018 08:02 | pressemeddelelse
Nuvaira Announces Oral Presentation at ERS International Congress Discussing Significance of Targeted Lung Denervation to Treat COPD
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum